Publication Archive

 

Merrill J, et al. LSM 2018 – Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.

View Publication

Ramsey-Goldman R, et al. LSM 2017 • Cell-bound complement activation products in SLE

View Publication

Buyon J, et al. LSM 2016 – Reduction in EC4d and anti-C1q antibodies associate with clinical improvement in SLE.

View Publication

Putterman C, et al. LSM. 2014. Cell_bound complement activation products in systemic lupus erythematosus.

View Publication

Wallace D, et al. LSM. 2016. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.

View Publication
 

AVISE SLE Monitor

AVISE SLE Monitor is indicated for the ongoing assessment of SLE disease activity.

Clinical Validity

Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus

Svenungsson E et al.

Rheumatology 2020

Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE.

Petri M et al.

Lupus Science & Medicine 2019

Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus.

Kao AH et al.

Transitional Stroke Research 2014

AVISE MTX

Avise MTX is indicated for RA patients receiving Methotrexate therapy as an objective measure of therapeutic exposure.

Clinical Validity

Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept.

Dervieux T et al.

Annals of the Rheumatic Diseases 2019

Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: A 76-week prospective study

Takahashi C et al.

RMD Open 2017

Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis.

Dervieux T et al.

Annals of the Rheumatic Diseases 2013

Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis.

Dervieux T et al.

Rheumatology 2010

Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.

Dervieux T et al.

Arthritis & Rheumatology 2006

Pharmacogentic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentered cross-sectional observation study

Dervieux T et al.

Annals of the Rheumatic Diseases 2005

Analytical Validity

Transition of methotrexate polyglutamate drug monitoring assay from venipuncture to capillary blood-based collection method in rheumatic diseases.

Brady K et al.

The Journal of Applied Laboratory Medicine 2019

Review Articles

Methotrexate: Optimizing the efficacy in rheumatoid arthritis. therapeutic advances in musculoskeletal disease.

Braun J et al.

Therapeutic Advances in Musculoskeletal Disease 2011

Toward a better understanding of methotrexate.

Kremer J et al.

Arthritis & Rheumatology 2004